Our immune therapy portfolio* is designed to recognize and kill highly multiple tumor targets. With more than 20 years of developing different immune therapies to treat blood cancers and solid tumors, GIMI has a broad and extensive portfolio of antigen targets for CAR-T  therapy, Engineered Immune Effector Cells (EIE) therapy, and Dendritic Cells (DC) vaccines.

In clinical studies, our immune therapy products have shown to be safe, contributing to durable anti-tumor responses.

Our portfolio immune therapy has been used to treat over 1000 patients in different clinical trials by our collaborators at the China Hospitals in both blood malignancies and solid tumors.

Several clinical studies are ongoing and planned with our different portfolio immune strategies. 

Developing innovative gene and immunological therapies for blood and solid tumor cancers, autoimmune and genetic diseases, and infectious diseases, GIMI has positioned itself in a broad frontline against genetic and autoimmune diseases, infections and cancer.

Based on positive results of the immunological products in various blood and solid tumor cancers, we are now pursuing acute myeloid leukemia as our lead indication with the goal of broadening patient treatment options. We are currently enrolling patients in the safety lead-in portion of our multicenter randomized Phase 2 AML study. See clinical trials**.